Advertisement
Wednesday 29 November 2016: Poster Sessions: Immunotherapy: Poster (Board P140)| Volume 69, SUPPLEMENT 1, S103-S104, December 2016

A phase I, open-label, multiple-ascending-dose trial to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of M7824, a novel bifunctional fusion protein targeting the PD-L1 and TGF-β pathways, in patients with metastatic or locally advanced solid tumors

DOI:https://doi.org/10.1016/S0959-8049(16)32906-9
A phase I, open-label, multiple-ascending-dose trial to investigate the safety, tolerability, pharmacokinetics, biological, and clinical activity of M7824, a novel bifunctional fusion protein targeting the PD-L1 and TGF-β pathways, in patients with metastatic or locally advanced solid tumors
Previous ArticleInterim results from the phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) in pancreatic cancer (PC), non-small cell lung cancer (NSCLC), and metastatic breast cancer (mBC)
Next ArticleCell based assays for immuno-oncology discovery research
      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      Article info

      Identification

      DOI: https://doi.org/10.1016/S0959-8049(16)32906-9

      Copyright

      © 2016 Elsevier Ltd. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX